NeuCyte and Grann Pharmaceuticals Announce Strategic Partnership to Accelerate mRNA-Based Therapies for Rare Neurological Diseases
​​
January 13, 2026 - NeuCyte, Inc, an induced-pluripotent stem cell-based biotechnology company, today announced a strategic partnership with Grann Pharmaceuticals, Inc., a biotechnology company developing mRNA-based lipid nanoparticle (LNP) protein replacement therapies. Together, the companies aim to accelerate the development and clinical translation of mRNA-based therapeutics, particularly for rare neurological diseases with high unmet need.
​
Grann Pharmaceuticals, Inc. (San Marcos, CA) recently completed an experimental mRNA-based treatment regimen (RTT-1) for Rett Syndrome and is advancing a growing pipeline of protein replacement therapies. Through this partnership, Grann’s mRNA-LNP delivery platform will be paired with NeuCyte’s human-relevant disease modeling capabilities to enable faster and more predictive preclinical development.
​
NeuCyte brings to the collaboration its New Approach Methodologies (NAMs), including patient-derived induced pluripotent stem cell (iPSC)–derived neuronal models, which are designed to establish therapeutic efficacy and accelerate pre-IND development using disease-relevant human systems. By combining these complementary technologies, this partnership seeks to shorten development timelines and improve confidence in translation from laboratory to clinic.
​
“NeuCyte is committed to using our platform to accelerate the development of viable therapeutics for neurological and neurodegenerative conditions,” said Tao Huang, CEO at NeuCyte, Inc. “We were particularly impressed by how rapidly Grann advanced from proof of concept to clinical treatment in Rett Syndrome, achieving this milestone in just 18 months. Together, we hope to achieve similar, or even faster, timelines for other rare diseases.”
​
“Grann Pharmaceuticals is pioneering lipid nanoparticle-based treatments for rare disease,” said. Tommy Temple, Co-founder and CEO of Grann Pharmaceuticals “NeuCyte’s success in establishing patient-derived iPSC neuronal models will help expand and de-risk our LNP-based portfolio for neurological and neurodegenerative diseases. This partnership brings together complementary strengths to more rapidly deliver therapies to patients who urgently need them.”
​
Together, NeuCyte and Grann Pharmaceuticals share a forward-looking vision: to transform how rare neurological diseases are treated by combining innovative delivery technologies with human-relevant biology, ultimately bringing effective therapies to patients faster.
​
About NeuCyte, Inc.
NeuCyte is a biotechnology company focused on CNS drug discovery. Building on its proprietary SynFire® technology for generating human iPSC-derived neural cells, NeuCyte has developed functional, human cell-based platforms to advance drug discovery efforts across neurodegenerative and neurological diseases.
​
For more information, visit www.neucyte.com
​
About Grann Pharmaceuticals
Grann Pharmaceuticals is a biopharmaceutical company dedicated to advancing mRNA lipid nanoparticle therapeutics for patients afflicted by diseases that are caused by the elimination of a particular human protein. Grann Pharmaceuticals achieves these goals by advancing the development of their nucleic acid-based lipid nanoparticle platform for therapeutic delivery.
​
For more information, visit www.grannpharma.com